HK:6127 JOINN Laboratories (China) Co., Ltd.

Joinn Laboratories (China) Co., Ltd. provides preclinical and non-clinical services. It evaluates various drugs, including biologics, pharmaceutical chemicals, and plant medicines for indications, such as renal, metabolic, cardiology, hematology, COPD, ophthalmic, oncology, and immune-related diseases. The company's services include screening services, such as efficiency screening, bioavailability, ADME screening, and non-GLP toxicology studies; pre-clinical safety assessment comprising general toxicology, safety pharmacology, developmental and reproductive toxicology, genetic and ocular toxicology, clinical pathology, analytical and bioanalytical analysis, immunology, and biomarker assays; pharmacodynamics services; and services to evaluate and optimize the absorption, distribution, metabolism, and elimination (ADME), as well as pharmacokinetic properties of potential drugs from early discovery projects. Its services also comprise clinical trials; a range of safety assessment services for medical devices, chemicals, and agrochemicals; regulatory consulting services in the areas of pharmaceuticals, biologics, Chinese medicine, medical devices, veterinary medicines, and agrochemicals; and food animal evaluation services comprising candidate selection, efficacy, safety evaluation studies on animals' health products, animal remedies, and fodders. In addition, the company offers traditional animals, such as outbred rats, inbred strain mice, outbred mice, and immunodeficient mice. It serves pharmaceutical, medical device, chemical, biotechnology, and agricultural development companies, as well as regulatory and other government agencies. It serves pharmaceutical, medical device, chemical, biotechnology, and agricultural development companies. The company operates in China, Europe, North America, Southeast Asia, and Australia. The company was founded in 1995 and is based in Beijing, China.

47.05 HKD
As of 08/12/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Unknown
Index country:  China
Country of incorporation:  China
IPO date:  02/26/2021
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   0 HKD
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy